Key terms
About NUVL
Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest NUVL news
Apr 17
4:48am ET
Nuvalent initiated with a Buy at Jefferies
Apr 08
4:37pm ET
Nuvalent presents data on NVL-330, zidesamtinib at AACR
Apr 01
9:50am ET
Crocs initiated, Bill downgraded: Wall Street’s top analyst calls
Apr 01
6:18am ET
Leerink more bullish on Nuvalent, upgrades to Outperform
Apr 01
6:08am ET
Nuvalent upgraded to Outperform from Market Perform at Leerink
Mar 27
6:06am ET
Nuvation Bio upgraded to Buy at Jefferies following acquisition of AnHeart
Feb 27
4:40pm ET
Analysts Offer Insights on Healthcare Companies: Nuvalent (NUVL) and Arcutis Biotherapeutics (ARQT)
Feb 27
4:32pm ET
Nuvalent assumed with a Buy at Guggenheim
Feb 27
1:50pm ET
Analysts’ Top Healthcare Picks: Esperion (ESPR), Nuvalent (NUVL)
Feb 27
1:40pm ET
Analysts’ Top Healthcare Picks: Privia Health Group (PRVA), Nuvalent (NUVL)
Feb 27
6:30am ET
Nuvalent granted breakthrough therapy designation to NVL-520 by FDA
Feb 23
9:37am ET
Block upgraded, Rivian downgraded: Wall Street’s top analyst calls
Feb 22
4:29pm ET
Baird starts Nuvalent at Outperform, sees ‘billion-dollar-plus opportunities’
Feb 22
4:23pm ET
Nuvalent initiated with an Outperform at Baird
Feb 12
6:35am ET
Nuvalent initiates Phase 2 portion of ALKOVE-1 trial
Jan 19
7:44am ET
Nuvalent price target raised to $80 from $70 at Piper Sandler
No recent press releases are available for NUVL
NUVL Financials
Key terms
Ad Feedback
NUVL Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
NUVL Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range